Opus Genetics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDOpus Genetics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings growth of 14% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.33 | +0.60% | ABOVE |
| 50 SMA | $4.93 | +8.82% | ABOVE |
| 100 SMA | $3.74 | +43.43% | ABOVE |
| 150 SMA | $3.17 | +69.22% | ABOVE |
| 200 SMA | $2.70 | +98.50% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IRD in an uptrend right now?
IRD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, IRD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is IRD overbought or oversold?
IRD's RSI (14) is 55. The stock is in neutral territory, neither overbought nor oversold.
Is IRD outperforming the market?
IRD has a Relative Strength (RS) Rating of 97 out of 99. Yes, IRD is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is IRD in its 52-week range?
IRD is trading at $5.36, which is 92% of its 52-week high ($5.82) and 91% above its 52-week low ($0.90).
How volatile is IRD?
IRD has a Beta of 1.13 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.